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In a rare moment of TV surfing at the weekend, I was transfixed by a lengthy advert that
appeared on the Sky News channel for 23andMe, the direct-to-consumer genetic testing
company, promoting its home testing kit, available for only £125, shipping included.
Hobbled by the US FDA in 2013 for infringing medical device regulations by suggesting it
could diagnose and predict health conditions, 23andMe launched in the UK in December
under the softer guise of infotainment. (1) It offers the ordinary citizen the chance to have
their genetic profile and family history analysed for a modest cost, like a sort of fortune
teller’s crystal ball that looks to the past, present and future.
The societal and ethical implications of such data uses are huge. Genetic data isn’t
exclusively the data-giver's, it also represents their relatives and can generate predictions
about them, not all of which they may wish to be known. This is made stronger by the
convergence with family histories (phenotypes) whose ownership is also debatable.
Critically the ownership of the enriched data assets these companies will eventually hold is
unclear and their potential value for commercial research is incalculable. 23andMe promises
that it won’t share people’s data with insurance companies or 'other interested parties',
without explicit consent, but it is free to use it for the purposes of its own medical research
(2) and the CEO was recently forced to defend its partnerships with major pharmaceutical
companies. (3) It comes as no surprise that data-hungry Google is one of 23andMe’s
backers, despite the recent uncoupling of their respective founders. (4)
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This raises important questions, not least about who is really the customer in this multi-
layered business model - is it the citizen paying for the test or external companies paying 
for their data, and who is gaining the most value from the relationship? It also raises 
questions about trust and the extent to which citizens purchasing these services truly 
understand what is being asked of them when they consent to uses of their data for 'medical
research'. Similar questions have arisen for related initiatives in the public sector, with the
UK Department of Health recently coming under fire for its handling of the consent
information given to participants in the 100,000 Genomes Project. (5)
As the digital dots join and companies converge the potential for our personal information,
and arguably our identities, to be siphoned off is just as great as the potential for innovation
to yield medical advances. Getting the balance right will require honesty and transparency.
The marketing of 23andMe as an entertaining curiosity belies its true power and is a cause
for concern.
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